Her research is dedicated to the clinical validation of the developed droplet-based procedures for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She has recently created (January 2012) a new Group, named Translational Research And Microfluidics (TRAM), within the clinical oncology research unit MEPPOT in the university Paris-Descartes. Baret (Max Plank Institute, Goettingen) and Raindance Technologies (US, now part of BIO-Rad). In particular, her team developed highly sensitive quantitative procedures for the detection of Cancer Biomarkers in droplets in a collaboration involving the clinical laboratory of Pr.
Starting from 2008, she focussed on the development of droplet-based digital procedures for Cancer diagnosis. Strasbourg), as a permanent CNRS researcher to work on HTS procedures using droplet-based microfluidics. Griffiths in the ISIS institute (created by Pr JM Lehn and directed by Pr T. In 2005, she integrated the Laboratory of Biological Chemistry directed by Pr. Greg Winter), to work on in vitro compartmentalization of biological and chemical reactions in emulsion droplets and participated to the development of High-throughput selection procedures of double-emulsions by FACS. She joined Andrew Griffiths’ group in 2003, in the Laboratory of Molecular Biology (LMB) in the Medical Research Council in Cambridge (UK, dir.
Laurent-Puig in the Cordeliers Research Center (CRC).Īfter graduation as a Molecular Toxicologist, Dr Valerie Taly (Abecassis) performed her PhD research at the Center of Molecular Genetics (CNRS, Gif-sur-Yvette, FR) on applications of combinatorial methods (generally used for proteins directed evolution) to the study of the functional plasticity of human Cytochromes P450. She is deputy director of this team headed by Prof. Dr Valerie Taly is a CNRS research director and group leader of the Translational Research And Microfluidics group within the MEPPOT team (Personalized medicine, pharmacogenomics and therapeutic optimization).
0 kommentar(er)
